Experienced in Prothrombin Deficiency

Dr. Catherine M. Broome

Mgmc LLC
Washington, DC
Experienced
in Prothrombin Deficiency
Specialties:Hematology Oncology | Hematology | Oncology
Accepting New Patients
40 Years of Experience
OverviewInsuranceLocationsClinical Research

Overview

Catherine Broome is a Hematologist Oncology specialist and a Hematologist in Washington, Washington, D.c.. Dr. Broome has been practicing medicine for over 40 years and is rated as an Experienced provider by MediFind in the treatment of Prothrombin Deficiency. Her top areas of expertise are Autoimmune Hemolytic Anemia, Thrombocytopenia, Chronic B-Cell Leukemia (CBCL), Bone Marrow Aspiration, and Splenectomy. Dr. Broome is currently accepting new patients.

Her clinical research consists of co-authoring 30 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
1985
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in DC
Hospital Affiliations
Medstar Georgetown University Hospital
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  UnitedHealthcare

Locations

MGMC LLC
3800 Reservoir Rd Nw, Washington, DC 20007
202-444-3700

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2024
Intervention Type: Other, Drug
Study Drug: Sapanisertib
Study Phase: Phase 2
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drugs: Cedazuridine, Decitabine
Study Phase: Phase 3
Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients With CLL/SLL
Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients With CLL/SLL
Enrollment Status: Terminated
Publish Date: August 02, 2024
Intervention Type: Procedure, Other
A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia
A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2024
Intervention Type: Drug
Study Drug: Rilzabrutinib
Study Phase: Phase 2
A Prospective, Multicenter, Randomized, Open-Label Phase 2, Parallel, Dose Ranging Multidose Study of Thrombosomes® vs Liquid Stored Platelets (LSP) in Bleeding Thrombocytopenic Patients
A Prospective, Multicenter, Randomized, Open-Label Phase 2, Parallel, Dose Ranging Multidose Study of Thrombosomes® vs Liquid Stored Platelets (LSP) in Bleeding Thrombocytopenic Patients
Enrollment Status: Terminated
Publish Date: May 25, 2023
Intervention Type: Biological
Study Drugs: Thrombosomes, Liquid-Stored Platelets
Study Phase: Phase 2
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Enrollment Status: Completed
Publish Date: May 25, 2023
Intervention Type: Drug
Study Drug: Fostamatinib
Study Phase: Phase 3
A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple- Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP)
A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple- Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP)
Enrollment Status: Completed
Publish Date: May 18, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion
Enrollment Status: Completed
Publish Date: December 23, 2022
Intervention Type: Drug
Study Drug: Sutimlimab
Study Phase: Phase 3
A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion
A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion
Enrollment Status: Completed
Publish Date: October 31, 2022
Intervention Type: Drug
Study Drug: Sutimlimab
Study Phase: Phase 3
A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Enrollment Status: Completed
Publish Date: July 21, 2021
Intervention Type: Drug
Study Drug: Fostamatinib
Study Phase: Phase 2
View 9 Less Clinical Trials

31 Total Publications

Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial - Authors' reply.
Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial - Authors' reply.
Journal: Lancet (London, England)
Published: June 06, 2024
Similar Doctors
Expertise in
23
conditions
Dr. Joseph P. Catlett
Hematology Oncology | Hematology
Expertise in
23
conditions
Dr. Joseph P. Catlett
Hematology Oncology | Hematology
110 Irving St Nw, Suite 2a38, 
Washington, DC 
 (3.5 mi)
202-877-2848
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joseph Catlett is a Hematologist Oncology specialist and a Hematologist in Washington, Washington, D.c.. Dr. Catlett and is rated as an Advanced provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Aspiration. Dr. Catlett is currently accepting new patients.

Expertise in
67
conditions
Dr. Stuart E. Selonick
Hematology Oncology | Hematology | Oncology
Expertise in
67
conditions
Dr. Stuart E. Selonick
Hematology Oncology | Hematology | Oncology

Maryland Oncology Hematology PA

10710 Charter Dr, Suite G020, 
Columbia, MD 
 (23.3 mi)
410-964-2218
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Stuart Selonick is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Selonick and is rated as a Distinguished provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Febrile Neutropenia, Familial Colorectal Cancer, Colorectal Cancer, and Thrombotic Thrombocytopenic Purpura. Dr. Selonick is currently accepting new patients.

Expertise in
16
conditions
Dr. Joseph M. Haggerty
Hematology Oncology | Hematology | Oncology
Expertise in
16
conditions
Dr. Joseph M. Haggerty
Hematology Oncology | Hematology | Oncology

Maryland Oncology Hematology PA

6420 Rockledge Dr, Suite 4200, 
Bethesda, MD 
 (8.4 mi)
301-929-0765
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joseph Haggerty is a Hematologist Oncology specialist and a Hematologist in Bethesda, Maryland. Dr. Haggerty has been practicing medicine for over 43 years and is rated as an Advanced provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Breast Cancer. Dr. Haggerty is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile